Virax Biolabs Group Ltd. (VRAX) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Virax Biolabs Group Ltd. (VRAX:NASDAQ), powered by AI.

Current Price
$0.15
P/E Ratio
-0.1
Market Cap
552,091
Sector
Healthcare
What is the Virax Biolabs Group Ltd. stock price forecast?

Virax Biolabs Group Ltd. is currently trading at $0.15. View real-time AI analysis on Alpha Lenz.

What is Virax Biolabs Group Ltd. insider trading activity?

View the latest insider trading data for Virax Biolabs Group Ltd. on Alpha Lenz.

What is Virax Biolabs Group Ltd.'s P/E ratio?

Virax Biolabs Group Ltd.'s P/E ratio is -0.1.

Virax Biolabs Group Ltd.

NASDAQ · VRAX
$0.15
Ask about Virax Biolabs Group Ltd.'s future dividend policy...
Alpha Chat Insight

Virax Biolabs Group Ltd. trades at a P/E of -0.1 (undervalued) with modest ROE of -109.6%.

Ask for details

Company Overview

Virax Biolabs Group Ltd. is a company specializing in the development and distribution of diagnostic testing kits and related products for the detection and management of viral diseases. The primary purpose of Virax Biolabs is to provide healthcare solutions that aid in the early detection of viral pathogens, a crucial step in preventing the spread of infectious diseases and enabling effective medical intervention. Its products are vital across various sectors including healthcare institutions, government health departments, and research organizations. The company's innovations are particularly significant amid global health crises, offering crucial tools for public health surveillance and response. By serving a diverse market, Virax Biolabs plays a key role in supporting public health initiatives and enhancing the capacity of healthcare systems to manage viral threats effectively. The company's operations underscore the importance of advancing medical diagnostics to safeguard community health and well-being.

CEOMr. James Foster
SectorHealthcare
IndustryBiotechnology
Employees19

Company Statistics

FY 2025

Profile

$552.09KMarket Cap
$6.33KRevenue
0.00Shares Out
19Employees

Margins

-838.21%Gross
-91649.46%EBITDA
-97344.76%Operating
-97992.31%Pre-Tax
-95833.71%Net

Valuation

-0.09P/E
0.10P/B
87.20EV/Sales
0.61EV/EBITDA
-0.11P/FCF

Growth (CAGR)

N/ARev 3Yr
-42.40%Rev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-101.88%ROA
-109.58%ROE
-103.19%ROIC

Financial Health

$4.23MCash & Cash Equivalents
$-3.26MNet Debt
17.66%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Virax Biolabs Group Ltd. (ticker: VRAX) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 19 employees. Market cap is $552,091.

The current price is $0.148 with a P/E ratio of -0.09x and P/B of 0.1x.

ROE is -109.58% and operating margin is -97344.76%. Annual revenue is $6,331.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Virax Biolabs Group Ltd. (Healthcare) Stock Forecast & Analysis $0.15 | Alpha Lenz